Leukemia
WIRB #2008-0370/Amgen #20060198: A Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk MDS
IRB #H-26101/SWOG #E1905: A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia with Multilineage Dysplasia
AML:
CIRB #2008-034C/CTSU #C10603: A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)
APL:
IRB #H-27313/SWOG #S0535: A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
Ancillary:
IRB #H-22821/SWOG #S9910: Leukemia Centralized Reference Labs & Tissue Repositories, Ancillary
IRB #H-22831/SWOG #9007: Companion Study for All Leukemia Studies: Comparison to All Leukemia Studies; Cyto-Genic Studies in Leukemia Patients
